Single-cell mapping of TMZ-resistant glioma reveals CXCL2/3-CXCR2-associated neutrophil communication

Wenwu Wan1, Pan Wang2, Bin Liao2

  • 1Chongqing Medical University, Chongqing, China; Department of Neurosurgery, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China.

Insights

Temozolomide resistance in glioblastoma is linked to tumor microenvironment interactions. A new gene signature identifies resistant cells and reveals a neutrophil communication pathway (CXCL2/3-CXCR2) that may be a therapeutic target.

Area of Science:

  • Oncology
  • Immunology
  • Genomics

Background:

  • Temozolomide (TMZ) resistance is a significant challenge in glioblastoma (GBM) treatment, limiting durable responses.
  • While tumor-intrinsic factors are studied, the role of the tumor microenvironment (TME) in TMZ resistance is not fully understood.

Purpose of the Study:

  • To identify molecular mechanisms and cellular interactions contributing to TMZ resistance in glioblastoma.
  • To define a gene signature for resistant glioma cells and explore their TME associations.

Main Methods:

  • Transcriptomic profiling of TMZ-resistant and control glioma cells.
  • Analysis of single-cell RNA-seq datasets using a derived gene signature.
  • CellChat analysis to investigate intercellular communication.
  • Functional assays assessing neutrophil migration and reactive oxygen species (ROS) production.

Main Results:

  • A prognostic gene signature identified distinct transcriptional subpopulations of resistant glioma stem-like cells.
  • Resistant cells showed increased crosstalk with immune cells, particularly microglia/macrophages.
  • A novel CXCL2/3-CXCR2 signaling axis was identified, promoting neutrophil migration and ROS production.

Conclusions:

  • A resistance-associated gene signature can delineate cellular states in gliomas.
  • A tumor-neutrophil communication circuit involving the CXCL2/3-CXCR2 axis is linked to TMZ resistance.
  • Targeting the CXCL2/3-CXCR2 pathway presents a potential strategy to overcome TMZ resistance in glioblastoma.